Donghui Liu, Shant Kumar, Jason Ashworth, Kamela Ali, Abdulmannan Fadel, Baoqiang Guo, Mark Slevin
Anticancer research 2021 MarCD105 is highly expressed on human activated endothelial cells (ECs), is an important component of the TGF-β1 receptor complex and is essential for angiogenesis. CD105 expression is up-regulated in activated ECs and is an important potential marker for cancer prognosis. In vitro rat myoblasts transfected with the L-CD105 and S-CD105 transfectants. The transfectants were treated with TGF-β1 for the angiogenesis study. L-CD105 affects cell proliferation in the presence and absence of TGF-β1, and inhibits p-ERK1/2, p-MEK1/2 and p-c-Jun in L-CD105 transfectants compared to controls. The induction of phospho-ERK1/2 following treatment with TGF-β1 remained significantly lower in L-CD105 transfectants compared to controls. L-CD105 inhibits the phosphorylation of ERK1/2, MEK1/2, c-Jun1/2/3, and associated signalling intermediates. CD105 modulates cell growth and TGF-β1 induced cell signalling through ERK-c-Jun expression. Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Donghui Liu, Shant Kumar, Jason Ashworth, Kamela Ali, Abdulmannan Fadel, Baoqiang Guo, Mark Slevin. CD105 (Endoglin): A Potential Anticancer Therapeutic Inhibits Mitogenesis and Map Kinase Pathway Activation. Anticancer research. 2021 Mar;41(3):1219-1229
PMID: 33788713
View Full Text